ð¨ The Battle for Affordable Medicines: Why the EU’s Approach to Patent Linkage Differs from the U.S. ð¨
In the ongoing saga of pharmaceutical innovation versus access, the European Union and the United States are taking markedly different paths—pa…
Two Roads to Generic Entry: Why the EU Refuses America’s Patent Linkage System Read Post »
In the high-stakes world of pharmaceuticals, innovation isn’t just about developing groundbreaking drugs — it’s also about navigating the complex legal and strategic landscape that determines market dominance. Recently, a seismic shift has emerged, thr…
Skinny Labels Are Now a Liability: How GSK v. Teva Rewrote Generic Drug Strategy Read Post »
ð¨ The Hidden Signals in the FDA Orange Book: Unlocking Strategic Litigation Insights for Pharma Giants ð¨
In the high-stakes world of pharmaceutical innovation, every move counts. Patent disputes, litigation strategies, and market exclusivity batt…
Paragraph IV Strategy: Extracting Litigation Signals from the FDA Orange Book Read Post »
In the high-stakes world of pharmaceuticals, timing isn’t just everything—it’s the difference between maximizing revenue and watching profits evaporate. As patent protections expire, drug companies face a critical crossroads: do they sit back and watch…
Sell More Packaging Before Patents Die: Target drug companies shifting to OTC post-LOE Read Post »
The AI Drug Race: Why Algorithms Don’t Own Patents—and How to Win the Innovation Battle
In the relentless pursuit of groundbreaking medicines, the pharmaceutical industry is at a pivotal crossroads. Today, artificial intelligence (AI) and machine learn…
Algorithms Don’t Own Patents: How to Win the AI Drug Race Read Post »
The Hidden Strategy Behind Pharma’s Sales Tactics: Playing on Fear, Not Features
In the high-stakes world of pharmaceuticals, the game isn’t just about innovation or patient outcomes—it’s often about understanding and manipulating the fears that drive …
Navigating the Patent Cliff: The 30-Month CDMO Playbook for Pharma’s Next Big Win
In the high-stakes world of pharmaceuticals, innovation isn’t just about groundbreaking discoveries—it’s also about strategic timing, regulatory agility, and operational …
Win the Patent Cliff: The 30-Month CDMO Playbook Read Post »
In the high-stakes world of pharmaceuticals, securing patent exclusivity isn’t just a legal hurdle—it’s a billion-dollar gamble. The recent article, "The Billion Dollar Equation: How to Win the Five-Year Fight for Patent Exclusivity," sheds l…
The Billion-Dollar Equation: How to win the five-year fight for patent exclusivity Read Post »
In the fiercely competitive world of pharmaceuticals, innovation isn’t just about developing groundbreaking drugs—it’s also about safeguarding those innovations from the relentless tide of generic competition. The recent article, "Building the Unb…
In today’s volatile global landscape, the resilience of the pharmaceutical supply chain isn’t just a strategic advantage—it’s a matter of life and death. Recent disruptions—from geopolitical tensions to pandemic-induced shortages—have exposed a stark v…